Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

BVXV BiondVax Pharmaceuticals Ltd

1,36

0,00 (0,00%)

10 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more BiondVax Pharmaceuticals Charts.

BiondVax Pharmaceuticals (NASDAQ:BVXV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more BiondVax Pharmaceuticals Charts.

News BiondVax Pharmaceuticals Ltd

Form NT 20-F - Notification of inability to timely file Form 20-F
Dienstag 30 April 2024 (2 Wochen vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Dienstag 16 April 2024 (4 Wochen vor) • Edgar (US Regulatory)

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG
Mittwoch 10 April 2024 (1 Monat vor) • PR Newswire (US)

Form SC 13D - General statement of acquisition of beneficial ownership
Dienstag 12 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Scinai leadership to attend BIO-Europe Spring 2024
Dienstag 12 März 2024 (2 Monate vor) • PR Newswire (US)

Scinai Welcomes Liat Halpert as Head of Business Development and Sales
Dienstag 13 Februar 2024 (3 Monate vor) • PR Newswire (US)

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
Donnerstag 4 Januar 2024 (4 Monate vor) • PR Newswire (US)

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule
Montag 20 November 2023 (6 Monate vor) • PR Newswire (US)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Donnerstag 7 September 2023 (8 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 6 September 2023 (8 Monate vor) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mittwoch 6 September 2023 (8 Monate vor) • Edgar (US Regulatory)

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
Mittwoch 6 September 2023 (8 Monate vor) • GlobeNewswire Inc.

Weitere BiondVax Pharmaceuticals Ltd News-Artikel

NLBNPIT1ZN22 20241220 40

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen